Heart failure & cardiomyopathies
Early Initiation of SGLT2 inhibitor and Mortality in Heart Failure With Reduced Ejection Fraction : A Target Trial Emulation Study
Main finding · All-cause mortalityResult — go to the resultRD −1.1 percentage points 95% CI −2.0 to −0.2Authors' conclusion
Initiation of an SGLT2i within 30 days of HFrEF diagnosis was associated with lower one-year mortality and HF hospitalization compared with no initiation. These findings support prioritizing early SGLT2i initiation as part of foundational therapy for HFrEF in routine clinical practice.
Study context
- Population
- Adults with incident heart failure with reduced ejection fraction (HFrEF) eligible for SGLT2i therapy, Danish nationwide registers, July 2020 to August 2024patients with incident HFrEF
- Participants
- 10,346 adults
- Comparison
- SGLT2i initiators vs Non-initiators
- SGLT2i initiatorsn = 3,268
- Non-initiatorsn = 7,078
- Outcome
- All-cause mortality
- Follow-up
- One year
Methodological detailsDanish nationwide register data, clone-censor-weight design
- Danish nationwide register data
- Clone-censor-weight design
Main finding
As reported in the abstract
RD
−1.1 percentage points
95% CI −2.0 to −0.2
Events by group
SGLT2i initiators
226
events
Non-initiators
637
events
SGLT2i initiators vs Non-initiators
RD −1.1 percentage points (95% CI −2.0 to −0.2)
Secondary outcomes
| Outcome | RD (percentage points) (95% CI) | |
|---|---|---|
| HF hospitalization (secondary outcome) · one year | −3.4 (−3.9 to −2.9) | |
| −4−202Difference, percentage points (linear scale) |
- HF hospitalization (secondary outcome): lower one-year risk of HF hospitalization with initiation within 30 days
Original publication
Early Initiation of SGLT2 inhibitor and Mortality in Heart Failure With Reduced Ejection Fraction : A Target Trial Emulation Study. Eur Heart J Cardiovasc Pharmacother. Published 26 October 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →